137 related articles for article (PubMed ID: 28498431)
1. PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients.
Sun G; Yang L; Dong C; Ma B; Shan M; Ma B
Oncol Rep; 2017 Jun; 37(6):3536-3542. PubMed ID: 28498431
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
3. High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival.
Zhang Y; Yang WK; Wen GM; Tang H; Wu CA; Wu YX; Jing ZL; Tang MS; Liu GL; Li DZ; Li YH; Deng YJ
Mol Genet Genomic Med; 2019 Nov; 7(11):e908. PubMed ID: 31513357
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer.
Zhou Y; Liu F; Xu Q; Yang B; Li X; Jiang S; Hu L; Zhang X; Zhu L; Li Q; Zhu X; Shao H; Dai M; Shen Y; Ni B; Wang S; Zhang Z; Teng Y
Oncogene; 2020 Aug; 39(34):5633-5648. PubMed ID: 32661323
[TBL] [Abstract][Full Text] [Related]
5. PRKDC is a prognostic marker for poor survival in gastric cancer patients and regulates DNA damage response.
Zhang Y; Wen GM; Wu CA; Jing ZL; Li DZ; Liu GL; Wei XX; Tang MS; Li YH; Zhong Y; Deng YJ; Yang WK
Pathol Res Pract; 2019 Aug; 215(8):152509. PubMed ID: 31255330
[TBL] [Abstract][Full Text] [Related]
6. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
Wang Y; Zhao H; Zhao P; Wang X
Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
8. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
9. Identification of PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) as an essential gene for colorectal cancer (CRCs) cells.
Sun S; Cheng S; Zhu Y; Zhang P; Liu N; Xu T; Sun C; Lv Y
Gene; 2016 Jun; 584(1):90-96. PubMed ID: 26992638
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
[TBL] [Abstract][Full Text] [Related]
11. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
12. LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.
Wang S; Zou Z; Luo X; Mi Y; Chang H; Xing D
Oncogene; 2018 Jun; 37(24):3243-3259. PubMed ID: 29545602
[TBL] [Abstract][Full Text] [Related]
13. Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome.
Jia L; Yang X; Tian W; Guo S; Huang W; Zhao W
Med Sci Monit; 2018 Nov; 24():8239-8249. PubMed ID: 30444219
[TBL] [Abstract][Full Text] [Related]
14. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
Sun S; Liang X; Zhang X; Liu T; Shi Q; Song Y; Jiang Y; Wu H; Jiang Y; Lu X; Pang D
Br J Cancer; 2015 Apr; 112(8):1332-9. PubMed ID: 25867275
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
[TBL] [Abstract][Full Text] [Related]
17. Down-regulated microRNA-124 expression as predictive biomarker and its prognostic significance with clinicopathological features in breast cancer patients.
Arabkheradmand A; Safari A; Seifoleslami M; Yahaghi E; Gity M
Diagn Pathol; 2015 Sep; 10():178. PubMed ID: 26415857
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL
Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583
[TBL] [Abstract][Full Text] [Related]
19. IL-10 and PRKDC polymorphisms are associated with glioma patient survival.
Hu M; Du J; Cui L; Huang T; Guo X; Zhao Y; Ma X; Jin T; Li G; Song J
Oncotarget; 2016 Dec; 7(49):80680-80687. PubMed ID: 27811370
[TBL] [Abstract][Full Text] [Related]
20. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
